Savara Inc.
SVRAHIGH VELOCITYFILING INTENSITYSavara Inc. reads as High Velocity (composite 70/100); pressure / disclosure signals dominate the posture this cycle · primary market Healthcare.
Lens
Disclosed M&A capital (2023–2025)
N/A
vs N/A in 2020–2022
Disclosed transactions
N/A
0/3 active fiscal years in window
Buyer archetype
Consistent Strategic Buyer
Meaningful spend appears across repeat years.
Composite score
70
High Velocity dominates · Filing Intensity
Behavioral posture, nine reads.
Each index scores the issuer 0–100 against an EDGAR-anchored definition. Scores ≥ threshold elevate the issuer into the index's constituent set; the dominant index drives the masthead label.
Active Acquirer
Companies actively deploying disclosed capital into M&A
- $542M disclosed buyer spend
Buyer Cadence
Buyer-side companies with recent filing activity
- Filed within 47d
- 398 8-Ks
Target Probability
Issuers showing target-side patterns from filings
- 14 activism filings
Spin/Carve
Issuers showing spin-off, carve-out, or sum-of-parts posture
- 14 activism filings
Pressure Watch
Issuers facing activism, governance, or control pressure
- 14 activism filings
- Latest activism 1.8y ago
Distress Watch
Issuers showing financial-distress filing patterns
- 10-Q 210d stale
- 14 activism filings
Restatement Risk
Issuers with accounting-integrity flags from filings
- 3 non-reliance 8-Ks
- 6 auditor changes
- 6 NT late filings
- Latest event 7.2y ago; heavily discounted
Capital Velocity
DominantIssuers with the highest filing-activity intensity
- 398 8-Ks
- 5 form types
Quiet Power
Large issuers with low signal volume and clean disclosure cadence
- Enterprise value $1.1B
- 10-Q 210d ago
- 3 active signals
Capital cadence.
Ten-year disclosed M&A activity. Bars show spend ($MM); ticks show recorded transaction count. Disclosure tier annotated where v6 audited corpus carries an entry.
Disclosed spend $MM Disclosed transactions (right axis)Peak spend year: $483M · Peak count: 2
| FY | Disclosed buys | Disclosed spend | Avg ticket | Audited tier |
|---|---|---|---|---|
| 2025 | N/A | N/A | N/A | N/A |
| 2024 | N/A | N/A | N/A | N/A |
| 2023 | N/A | N/A | N/A | N/A |
| 2022 | N/A | N/A | N/A | N/A |
| 2021 | N/A | N/A | N/A | N/A |
| 2020 | N/A | N/A | N/A | N/A |
Strategy posture.
The buyer's playbook in terms of strategic archetype: what each disclosed move says about how they're deploying capital.
Archetype mix
- Technology Acquisition33%
- Platform33%
- Bolt On33%
Strategy keywords
Terms recurring across recent 10-K acquisition disclosures.
- technology_acquisition
- platform
- bolt_on
Filing language.
Direct excerpts from acquisition disclosures and strategy sections: the verbs the buyer chose, in the filings they signed.
“We believe up to 80% of the U.S. markets for ANX-530 and ANX-514 are concentrated within eight to ten GPOs and that a focused, specialized sales force may be able to effectively market and sell our products, if approved, through these organizations.”
“As consolidation within the industry and attempts to further enhance economies of scale and marketing advantages continue, we believe these markets will concentrate further.”
“we acquired SynthRx, Inc. as a company whose lead product candidate was a strong fit with our pipeline expansion strategy”
“We acquired SynthRx to expand our product pipeline, enter into new therapeutic areas and address unmet market needs.”
“We acquired AIR001 in February 2014 through our acquisition of Aires Pharmaceuticals, Inc.”
Market context.
Where this issuer sits inside its SE-Cluster rollup wedge, with disclosed-spend rank plus trading comparables against the public peer set.
Primary market
Healthcare
- Market spend (2023–2025)
- $195B
- Market spend (2020–2022)
- $253.6B
- Recent vs prior
- −23%
- Issuer rank in market
- N/A
- Share of market capital
- 0.0%
Valuation positioning
SVRA trades at a -21.7-turn discount to the Healthcare peer median of 12.9×.
- EV / Revenue
- N/A
- Net debt / EBITDA
- N/A
- Peer median EV / EBITDA
- 12.9×
Trading comparables
FMP market data · 2026-05-10
| Company | EV / EBITDA | EV / Rev | Net debt / EBITDA | Revenue | M&A 2023–2025 |
|---|---|---|---|---|---|
AbbVie Inc.ABBV | 23.4× | 6.7× | 3.1× | $62.8B | $18B |
| 17.2× | 0.9× | 1.9× | $449.7B | $28.1B | |
Amgen Inc.AMGN | 12.9× | 6.0× | 2.6× | $37.2B | $26.7B |
| 11.7× | 0.5× | 2.5× | $200.4B | $6.4B | |
| 9.3× | 1.9× | 2.8× | $76.4B | $1.3B |
Trading multiples from FMP market data; disclosed M&A spend from the SE-Cluster EDGAR 10-K corpus. Peer set = top disclosed buyers in Healthcare. Bars scaled to the highest EV/EBITDA in the set.
Buyer landscape.
Public buyers whose stated archetypes, target categories, and recent cadence align with this issuer as a plausible acquisition target. Scores cross EDGAR signal and disclosure overlap.
Likely buyers
No public buyers surface as a strong target-side fit on current signal.
Likely sellers / divestiture partners
No reciprocal divestiture / strategic-alternatives matches identified.
Filing activity & signal stream.
Filing cadence and event-driven signals visible on EDGAR. The signal stream below is curated from restatement / spin-carve / activism categories, providing context for any near-term call.
Filing cadence
- 10-K (annual)242026-03-13
- 10-Q (quarterly)662025-11-12
- 8-K (event)3982026-03-13
- Proxy / DEF 14A402026-04-24
- Activism (13D / DFAN / PREC)142024-08-14
Signals on file
- critical
Non-reliance disclosure
2009-03-253 Item 4.02 filings on file; financial-statement non-reliance.
- elevated
Auditor change
2019-04-156 Item 4.01 filings on file; certifying accountant change.
- watch
Late-filing notice
2003-03-286 NT 10-K/10-Q filings on file.
- elevated
Activism on file
2024-08-1414 activist filings on file (13D, DFAN14A, PREC14A series).
- info
Signal
Serial acquisition history
- info
Signal
10-K strategy themes
- info
Signal
Restatement risk
Audited corpus.
No audited record on file for this CIK in the current v6 corpus.
This issuer has not been extracted into the v6 audited acquirer corpus yet. The brief above pulls from ranking-level aggregates and issuer-index signal only.